Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | ICMT | O60725 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587822 | 0.87 | MAPT (0.36) | MAPTALDH1A1PPARGPPARAKDM4E | |
| SCHEMBL4587000 | 0.81 | ARG1 (0.33) | ALDH1A1 | |
| SCHEMBL4588338 | 0.81 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4588333 | 0.81 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4585907 | 0.80 | MAPT (0.37) | MAPTALDH1A1PPARGPPARAKDM4E | |
| SCHEMBL4586125 | 0.80 | MAPT (0.37) | MAPTALDH1A1PPARGPPARAKDM4E | |
| SCHEMBL4587226 | 0.80 | CYP1A2 (0.33) | SMN1; SMN2 | |
| SCHEMBL4587221 | 0.80 | CYP1A2 (0.33) | SMN1; SMN2 | |
| SCHEMBL4587560 | 0.79 | NOD1 (0.35) | — | |
| SCHEMBL4587564 | 0.77 | TSHR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | MAPT 3734/4885ALDH1A1 567/4885PPARG 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.